OncoPrism Immunotherapy Response Assay
Multiple Solid Tumors (11 types in PREDAPT trial)
Clinical TrialActive
Key Facts
Indication
Multiple Solid Tumors (11 types in PREDAPT trial)
Phase
Clinical Trial
Status
Active
Company
About Cofactor Genomics
Cofactor Genomics is a private, commercial-stage diagnostics company leveraging its proprietary ImmunoPrism RNA-Seq platform to build multidimensional predictive biomarkers for immuno-oncology. The company's lead program, the OncoPrism assay, is under investigation in the multi-center PREDAPT trial across 11 solid tumor types to predict immunotherapy response. Cofactor operates a CAP/CLIA laboratory and offers both Research Use Only products and Laboratory Developed Tests (LDTs), aiming to improve clinical trial success and patient treatment decisions through precise immune profiling.
View full company profile